Navigation Links
CBIS Releases Corporate Operational Guidance for 2013 as the Company Reorganizes to better meet the Growing Global Crisis Associated with Anti-Retroviral Drug Resistance among People with AIDS, as well as the Increasing Need for Patient Friendly Ski
Date:1/31/2013

CC-1

Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas. The Company has begun preclinical investigations, which are being initiated in Europe for squamous and basal cell carcinomas and Kaposi's Sarcoma, based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

About Kaposi's Sarcoma 

Kaposi's Sarcoma (KS) was one of the first recognized AIDS-defining opportunistic infections and is the most common HIV-associated neoplasm and cancer in equatorial Africa.  AIDS-associated KS is a disseminated, aggressive disease with extremely limited treatment options.  While the incidence of KS significantly decreased in the developed world with the advent of and access to highly active antiretroviral therapy (HAART), increasing drug resistance in treatment-experienced patients has led to a resurgence of KS in people living with HIV.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.

Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," o
'/>"/>

SOURCE Cannabis Science, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
2. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
3. ShelfX Releases A Fridge That Knows What You Took
4. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
5. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
6. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
7. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
8. MD Bioproducts releases HLA-B27 subtype specific antibody.
9. ChemDAQ Releases First Sensor For Detection Of Peracetic Acid In Air
10. Polar Releases H7, a Preeminent Wireless Heart Rate Sensor with Bluetooth Smart
11. NanoMarkets Releases New Report on Thin-Film and Printed Batteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. , Titled "Evidence-Conformant ... developed at UH to enhance care for adult cancer ... for high health care utilization. , "We ...
(Date:7/10/2014)... illness and even death are likely to result if ... Now, however, a team of researchers based at The ... order of infection, the bacteria Streptococcus pneumoniae ... case of the flu. , The researchers discovered ... a bacterial virulence factor, might protect macrophagesa type of ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/9/2014)... 2014 -- The World Health Organization recommends that youth ... to vigorous physical activity (MVPA) each day. Studies ... during school hours. Therefore, it stands to reason ... MVPA. In a new study scheduled for publication ... that time spent outdoors after school was positively associated ...
(Date:7/9/2014)... had an aneurysm, she figured an invasive brain surgery and ... said Wakulich, who is 56 years old and lives in ... Then I met Dr. Bernard Bendok who told me about ... was something I didn,t even know was an option." , ... to evaluate the safety and effectiveness of the Microvention Inc. ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:New type of stent could help some brain aneurysm patients 2
... Department of Defense (DOD) Breast Cancer Research Program (BCRP) ... Programs has awarded Silvia Formenti, MD, the Sandra and ... Radiation Oncology a $4.5 million Multi-Team Award to conduct ... offers tremendous promise for new therapeutic options for patients ...
... News) -- Certain gene mutations influence how likely people ... counter to experience, say researchers at Brown University. ... without gene mutations that affect the activity of the ... the prefrontal cortex and the striatum. The prefrontal ...
... TUESDAY, April 19 (HealthDay News) -- Nearly one-third of ... experience depression after the injury, a new study finds. ... existing research on blunt force trauma head injuries suffered ... "Any patient who has a traumatic brain injury ...
... release is available in German . ... consequences: Around first grade, the children start experiencing vision ... complete blindness. This is the first indication of a ... experience hallucinations, epileptic seizures, dementia and, finally, failure of ...
... glioma from chemoradiation may result in improved patient survival, ... Kimmel Cancer Center at Jefferson suggests. These ... the British Journal of Cancer . The ... such as fatigue and loss of short-term memory, that ...
... implants appear to be associated with a rare form of lymphoma, ... is caused by implants or to suggest an underlying mechanism for ... from the RAND Corporation. The study, published online by ... the disease takes a slow course and can be controlled by ...
Cached Medicine News:Health News:NYU Langone Medical Center awarded $4.5 million for breast cancer research 2Health News:Depression Common After Brain Injury 2Health News:Hope for children with rare genetic defect 2Health News:Hope for children with rare genetic defect 3Health News:Minimizing side effects from chemoradiation could help brain cancer patients live longer 2Health News:Study confirms link between breast implants and rare form of cancer 2Health News:Study confirms link between breast implants and rare form of cancer 3
Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....
... RTVue is an ultra-high speed, high resolution ... for retina imaging and analysis. ... Fourier-Domain Optical Coherence technology just emerging from ... The ultra-high speed and high ...
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
Medicine Products: